Gilead Sciences (Nasdaq: GILD) Kite unit has agreed a collaboration and research deal with Epicrispr Biotechnologies (Epic Bio), using the latter’s proprietary gene regulation platform to develop next-generation cancer cell therapies.
The agreement will allow Kite to leverage the licensed technology to modulate certain genes to potentially enhance CAR T-cell functionality.
This adds to the worldwide license agreement Kite entered last year Refuge Biotechnologies, for its highly modular platform to regulate target antigen-dependent gene expression as a means to improve upon both the efficacy and safety of first-generation CAR T-cell therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze